

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of the Claims:

Claim 1. (currently amended) An osmotic system for delivering a pharmaceutically active agent, comprising:

a core portion, wherein said core portion includes said pharmaceutically active agent at a first concentration;

a layer portion enclosing and directly adjacent to said core portion, wherein said layer portion includes said pharmaceutically active agent at a second concentration, said second concentration being greater than said first concentration; and

a semipermeable wall portion enclosing said core portion and said layer portion.

Claim 2. (original) The system of Claim 1 wherein said pharmaceutically active agent is a protein or peptide.

Claim 3. (original) The system of Claim 1 wherein said semipermeable wall portion is formed from cellulose acetate.

Claim 4. (original) The system of Claim 1 wherein said pharmaceutically active agent is present in said portion in an amount of about 60 wt. %.

Claim 5. (original) The system of Claim 1 wherein said pharmaceutically active agent is present in said layer portion in an amount of about 90 wt. %.

Claim 6. (previously amended) The system of Claim 1 wherein said pharmaceutically active agent is pseudoephedrine or its salts.

Claim 7. (currently amended) An osmotic system for delivering a first pharmaceutically active agent and a second pharmaceutically active agent, comprising:

a core portion, wherein said core portion includes said first pharmaceutically active agent at a first concentration;

a first layer portion enclosing and directly adjacent to said core portion, wherein said layer portion includes said first pharmaceutically active agent at a second concentration, said second concentration being greater than said first concentration;

a semipermeable wall portion enclosing said core portion and said first layer portion; and

a second layer portion including a second pharmaceutically active agent, said second layer enclosing said semipermeable wall portion.

Claim 8. (original) The system of Claim 7 wherein said first pharmaceutically active agent is present in said core portion in an amount of about 60 wt. %.

Claim 9. (original)) The system of Claim 7 wherein said first pharmaceutically active agent is present in said first layer portion in an amount of about 90wt. %.

Claim 10. (original) The system of Claim 7 wherein said second pharmaceutically active agent is present in said second layer portion in an amount of from about 2 wt. % to about 99 wt.%.

Claim 11. (original) The system of Claim 10 wherein said second pharmaceutically active agent is present in said second layer portion in an amount of from about 60 wt. % to about 95 wt.%.

Claim 12. (previously presented) The osmotic system of claim 1, wherein said pharmaceutically active agent is an antitussive, antihistamine, expectorant or decongestant.

Claim 13. (previously presented) The osmotic system of claim 12, wherein said pharmaceutically active agent is chlorpheniramine or its salts, diphenhydramine, or dimenhydramine.

Claim 14. (previously presented) The osmotic system of claim 1, wherein said pharmaceutically active agent is cyclosporin, carmustine, carbamazepine, desmopreson, dihydroergotamine, fluorouracil, heparin sodium, ribavirin, sumatriptan succinate, flutamide, naltrexone HCl, terbutaline sulfate, triamterene, terazosin, parazosin, nifedipine, calcitonin, insulin, parathyroid hormone, or GLP-1.

Claim 15. (previously presented) The osmotic system of claim 7, wherein said first pharmaceutically active agent is an antitussive, antihistamine, expectorant or decongestant.

Claim 16. (previously presented) The osmotic system of claim 15, wherein said first pharmaceutically active agent is chlorpheniramine or its salts, diphenhydramine, or dimenhydramine.

Claim 17. (previously presented) The osmotic system of claim 15, wherein said first pharmaceutically active agent is pseudoephedrine or its salts.

Claim 18. (previously presented) The osmotic system of claim 7, wherein said first pharmaceutically active agent is cyclosporin, carmustine, carbamazepine, desmopreson, dihydroergotamine, fluorouracil, heparin sodium, ribavirin, sumatriptan succinate, flutamide, naltrexone HCl, terbutaline sulfate, triamterene, calcitonin, insulin, parathyroid hormone, or GLP-1.

Claim 19. (previously presented) The osmotic system of claim 15, wherein said second pharmaceutically active agent is loratidine, desloratidine, astemizole, norastemizole or ebastine.

Claim 20. (previously presented) The osmotic system of claim 7, wherein said first pharmaceutically active agent is pseudoephedrine or its salts, and said second pharmaceutically active agent is loratidine.